Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK0524A Dose Selection for Niacin-Induced Flushing
NCT00533676Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2004
- Primary completion
- Dec 2006
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of laropiprant + niacin in dyslipidemia, sponsored by Merck & Co.. Started Aug 2004; status: completed.
02
Drugs
laropiprant + niacin
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT00533676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00533676.